New drug could reduce need for plasma exchange in rare blood disorder
NCT ID NCT05714969
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no plasma exchange (a procedure that cleans the blood). Participants received TAK-755 during an acute attack and for up to 6 weeks afterward, and were monitored for about 3 months for safety and response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AKH - Medizinische Universitat Wien
Vienna, 1090, Austria
-
Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
Torino, 10126, Italy
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, 57010, Greece
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, 41010, Spain
-
Hospital de Cruces
Barakaldo, Vizcaya, 48903, Spain
-
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina, 27858, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8XP, United Kingdom
-
Rutgers University
New Brunswick, New Jersey, 08901, United States
-
University College London Hospital
London, Greater London, NW1 2PG, United Kingdom
-
University of Florida - Shands
Gainesville, Florida, 32610, United States
-
University of Minnesota Clinical Research Unit
Minneapolis, Minnesota, 55455, United States
-
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132, United States
-
Versiti Wisconsin, Inc.
Milwaukee, Wisconsin, 53226, United States
-
Weill Cornell
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug could keep rare blood disease in check
- Scientists hunt for relapse clues in TTP Patients' immune cells
- New enzyme replacement therapy aims to stop dangerous blood clots in rare disease
- New hope for rare blood disorder: study reviews real-world use of enzyme therapy
- New enzyme therapy shows promise in controlling rare blood clotting disorder
- Could a needle replace a machine? new study aims to simplify lifesaving iTTP treatment